PALB2 and ovarian cancer: Even for those tested during adulthood, the robust recall of an individual with a GPV in, for example, PALB2 at 25–30 years for breast cancer surveillance, then again at 50 years of age regarding ovarian cancer risk management, requires careful coordination with inbuilt failsafes.